Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  Sanofi    SAN   FR0000120578


News SummaryMost relevantAll newsSector news 

SANOFI : EMA Recommends Approval Of Sanofi Pediatric Vaccine Hexyon/Hexacima 6-in-1

02/22/2013 | 07:58am US/Eastern

PARIS--The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended market approval for Sanofi Pasteur's 6-in-1 pediatric vaccine, French drugs giant Sanofi (>> SANOFI) said Friday.


- Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.

- The new vaccine will be commercialized under the brand name Hexyon in Western European countries by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima in Eastern European countries by Sanofi Pasteur.

- The vaccine "reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases," said Olivier Charmeil, President and CEO of Sanofi Pasteur.

-Hexyon/Hexacima would be indicated for primary and booster vaccination of infants from six weeks of age in accordance with official recommendations.

- The CHMP positive opinion is supported by results of multi-center clinical studies involving approximately 5,000 infants; phase III clinical studies comparing Hexyon/Hexacima to licensed combination vaccines demonstrated that HexyonTM/HexacimaTM is safe and induces a robust immune response against all six targeted diseases.

-Write to Mimosa Spencer at

Subscribe to WSJ:

Stocks mentioned in the article : SANOFI
React to this article
Latest news on SANOFI
04/24 KERYX BIOPHARMACEUTICALS : Change in Directors or Principal Officers (form 8-K)
04/24 SANOFI : Playing Safe With Your Food
04/24 GENZYME : Commences Phase 2a Clinical Trial to Evaluate Oral Therapy for Fabry D..
04/24 SANOFI : MILITARY $2.08 Million Federal Contract Awarded to Sanofi Pasteur
04/23 SANOFI : Effect of Genzyme’s Multiple Sclerosis Treatment Lemtrada® (alemt..
04/23 SANOFI : Effect of Genzyme's Multiple Sclerosis Treatment Lemtrada® (alemtuzumab..
04/22 SANOFI : Findings from Sanofi Broaden Understanding of Environmental Molecular M..
04/22 SANOFI : New Hepatitis Data Have Been Reported by Investigators at Sanofi Pasteu..
04/22 GENZYME : Studies from Genzyme Corporation Add New Findings in the Area of Chole..
04/22 SANOFI : Earth Day 2015 at Sanofi
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes